RecruitingPHASE1, PHASE2NCT06282965
Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury
Studying Moderate and severe traumatic brain injury
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Arizona
- Principal Investigator
- Bellal Joseph, MDUniversity of Arizona
- Intervention
- Angiotensin (1-7)(drug)
- Enrollment
- 90 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (1)
- University of Arizona, Tucson, Arizona, United States
Collaborators
United States Department of Defense
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06282965 on ClinicalTrials.govOther trials for Moderate and severe traumatic brain injury
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT06866691Seizure Prevention in Traumatic Brain Injury With Levetiracetam and LacosamideWake Forest University Health Sciences
- RECRUITINGNANCT06241482Safety and Efficacy of Enhanced Recovery After Surgery in Neurocritical CareShanghai 6th People's Hospital
- RECRUITINGPHASE1NCT05716048Combinatory Rehabilitation Used for Substantially Helping Individuals With Traumatic Brain InjuryKessler Foundation
- ACTIVE NOT RECRUITINGNANCT05636020Intervention to Change Affect Recognition and EmpathyIndiana University
See all trials for Moderate and severe traumatic brain injury →